Where things stand
Last reviewed: October 23, 2026. All candidates are investigational and unapproved.
| Candidate | Developer | Type | Latest status |
|---|---|---|---|
| YCT-529 Investigational · Not approved | YourChoice Therapeutics | Daily oral pill, non-hormonal | Phase 1a (16 men, single doses) completed June 18, 2024 [1][2]. Phase 1b/2a repeat-dose study (28, 90 or 180 days; estimated 88 men; New Zealand) started Sept 11, 2024 and is listed as recruiting, with a listed completion date of July 31, 2026 [3]. |
| NES/T gel Investigational · Not approved | Contraline (developed by Population Council with NICHD) | Daily hormonal skin gel (segesterone acetate + testosterone) | Global Phase 2b completed, 462 couples at 17 sites; company anticipates starting Phase 3 in 2027; $92.5M Series B announced June 2, 2026 [4][5]. |
| ADAM Investigational · Not approved | Contraline | Non-hormonal hydrogel placed in the vas deferens | First-in-human study (25 men, Australia) listed completed March 8, 2026 [6]. Contraline reported regulatory approval for a Phase 2 study in Australia in April 2025 [7]. |
Trial registry entries can lag real-world progress. We update this page when a developer, registry or peer-reviewed journal publishes new information.
Sources
- ClinicalTrials.gov: NCT06094283 (YCT-529 Phase 1a)
- Communications Medicine (2025): Safety and pharmacokinetics of YCT-529
- ClinicalTrials.gov: NCT06542237 (YCT-529 Phase 1b/2a)
- Contraline: $92.5M Series B announcement, June 2, 2026
- Contraline pipeline page
- ClinicalTrials.gov: NCT05134428 (ADAM first-in-human)
- Contraline: ADAM 24-month milestone, April 24, 2025